Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Supply volumes for GBS-007 were adjusted due to changes in the competitive environment and market demand. Optimized supply prices, lower manufacturing costs, decreases in research and development expenses and other SG&A expenses, and gains on the sale of investment securities drove profit higher.
There is a description of material events and other matters. While events such as net losses in previous fiscal years, negative operating cash flow, and planned research and development investments have raised doubts, the company has determined that no material uncertainty exists. There are no applicable matters to disclose regarding the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥2,475 million (YoY -24.5%) |
| Operating profit | ¥486 million (YoY +125.9%) |
| Ordinary income | ¥463 million (YoY +504.2%) |
| Profit attributable to owners of the parent | ¥593 million (YoY +880.2%) |
| Net income per share | ¥11.88 |
| Equity ratio | End of the current fiscal period 34.9 / End of previous period 26.4 |
| Total assets | ¥6,422 million |
| Net assets | ¥2,279 million |
| Cash flows from operating activities | -22,429 thousand yen |
| Cash flows from investing activities | 305,165 thousand yen |
| Cash flows from financing activities | -149,974 thousand yen |
| Cash and cash equivalents at end of period | 3,441,643 thousand yen |
| Full-year earnings forecast | Net Sales 5,000～5,500 / Operating profit 100～500 / Ordinary income Not disclosed / Net income Not disclosed |
| Revision to Earnings Forecast | Net Sales Not disclosed → 5,000～5,500 / Operating profit Not disclosed → 100～500 / Ordinary income Not disclosed / Net income Not disclosed |
| Annual Dividend Forecast | 0 yen → 0 yen（0.0%） |
| Depreciation and amortization | 60 thousand yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of property, plant and equipment 636 thousand yen, Gain on sale of investment securities 221,717 thousand yen, Gain on reversal of stock acquisition rights 14,179 thousand yen, Reversal gain on cancellation of lease agreements 18,819 thousand yen, Gain on reversal of asset retirement obligations 614 thousand yen / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | There is a description of material events and other matters. While events such as net losses in previous fiscal years, negative operating cash flow, and planned research and development investments have raised doubts, the company has determined that no material uncertainty exists. There are no applicable matters to disclose regarding the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New None / Excluded None / Company name Not disclosed |
| Material subsequent events | The disclosure states that 4 companies entered into a share subscription agreement in November 2026 to subscribe for common shares issued by Alfenax Biologics株式会社. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 50,604,188 shares |
| Treasury Shares at Period-End | 144 shares |
| Factors Behind Changes in Business Performance | Supply volumes for GBS-007 were adjusted due to changes in the competitive environment and market demand. Optimized supply prices, lower manufacturing costs, decreases in research and development expenses and other SG&A expenses, and gains on the sale of investment securities drove profit higher. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main factor behind revenue was an adjustment in supply volumes for GBS-007 due to changes in the competitive environment and market demand. The company explained that profit was supported by the optimization of supply prices, lower manufacturing costs, decreases in research and development expenses and other SG&A expenses, and gains on the sale of investment securities.